Cristina Suárez

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Mauricio Burotto et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

David F. McDermott, Mahrukh Huseni, Michael B. Atkins et al. · Nature Medicine · 2018 · 1.2K citations · Full text

Urology, Genitourinary Cancer, Medicine +9

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Brian I. Rini, Thomas Powles, Michael B. Atkins et al. · The Lancet · 2019 · 988 citations

Urology, Genitourinary Cancer, Medicine +7

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Thomas Powles, Mark Kockx, Alejo Rodríguez‐Vida et al. · Nature Medicine · 2019 · 555 citations · Full text

Urology, Biomarker Analysis, Genitourinary Cancer +7

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Thomas Powles, Michiel S. van der Heijden, Daniel Castellano et al. · The Lancet Oncology · 2020 · 485 citations · Full text

Surgical Oncology, Urology, Metastatic Urothelial Carcinoma +8